Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials

Clinical Rheumatology
Sumit KunwarFlorina Constantinescu

Abstract

Janus kinases (JAKs) play an important role in intracellular signaling for multiple cytokines in the pathogenesis of RA. Baricitinib is an oral, selective JAK 1 and 2 inhibitor which has been shown to be effective in the treatment of RA in several clinical trials. This meta-analysis aims to aggregate currently available data to assess the overall efficacy and safety of baricitinib in RA. We searched PubMed, EMBASE, and Cochrane CENTRAL from inception through 09/24/17 with restriction to English language. We excluded meeting abstracts without full text publication. We used RevMan 5.3 to perform meta-analysis between groups on baricitinib (2 and 4 mg daily) and placebo using random effect model calculating odds ratio (OR) as well as 95% confidence interval (CI). Compared to placebo, 2 mg of baricitinib was more effective in achieving ACR20 [54 vs. 36.6%; OR 2.09; 95% CI 1.60-2.71; p < 0.00001; I2 0%], ACR50 [31.6 vs. 10.3%; OR 2.3; 95% CI 1.68-3.15; p < 0.00001; I2 0%], and ACR70 responses [18.7 vs. 5.1%; OR 4.05; 95% CI 2.54-6.44; p < 0.00001; I2 0%]. Similarly, 4 mg of baricitinib daily was more effective than placebo. Baricitinib 2 mg once daily did not increase any adverse events [65.3 vs. 62.4%; OR 1.03; 95% CI 0.80-1.34; p ...Continue Reading

References

May 17, 2000·Journal of Clinical Epidemiology·J L Tang, J L Liu
Jul 12, 2002·Statistics in Medicine·Julian P T Higgins, Simon G Thompson
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Apr 11, 2007·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·John P A Ioannidis, Thomas A Trikalinos
Sep 18, 2007·Best Practice & Research. Clinical Rheumatology·Sophia M Naz, Deborah P M Symmons
Jan 1, 2008·Arthritis and Rheumatism·Charles G HelmickUNKNOWN National Arthritis Data Workgroup
Apr 26, 2008·BMJ : British Medical Journal·Gordon H GuyattUNKNOWN GRADE Working Group
May 6, 2008·BMJ : British Medical Journal·Gordon H GuyattUNKNOWN GRADE Working Group
Feb 23, 2010·International Journal of Surgery·David MoherUNKNOWN PRISMA Group
Mar 3, 2010·The Korean Journal of Internal Medicine·Steven S StorageDaniel E Furst
Mar 11, 2010·Annals of the Rheumatic Diseases·Josef S SmolenUNKNOWN T2T Expert Committee
Apr 7, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jordan S FridmanKris Vaddi
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
May 15, 2015·Annals of the Rheumatic Diseases·Josef S SmolenDesirée van der Heijde
Nov 8, 2015·Arthritis & Rheumatology·Jasvinder A SinghTimothy McAlindon
Mar 31, 2016·The New England Journal of Medicine·Mark C GenoveseJosef S Smolen
Feb 16, 2017·The New England Journal of Medicine·Peter C TaylorYoshiya Tanaka
Mar 4, 2017·Therapeutic Advances in Musculoskeletal Disease·Bindee KuriyaEd Keystone
Mar 16, 2017·Drugs·Anthony Markham
Jul 25, 2017·Expert Opinion on Pharmacotherapy·Christophe RichezBernard Bannwarth
Nov 7, 2017·Nature Reviews. Drug Discovery·Daniella M SchwartzJohn J O'Shea
Dec 3, 2017·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Abril VerdenKeith B Hoffman
Feb 10, 2018·Current Medicinal Chemistry·Felice RivelleseFrancesca Wanda Rossi
Feb 21, 2018·Current Opinion in Rheumatology·Tina D Mahajan, Ted R Mikuls

❮ Previous
Next ❯

Citations

Mar 17, 2020·Expert Opinion on Drug Safety·Suguru Honda, Masayoshi Harigai
Dec 12, 2018·American Journal of Clinical Dermatology·Helen He, Emma Guttman-Yassky
Jul 14, 2020·Therapeutic Advances in Musculoskeletal Disease·Flavia SunziniStefan Siebert
Jan 20, 2019·Zeitschrift für Rheumatologie·H-M Lorenz, C Kneitz
May 20, 2020·Pharmaceuticals·Maha Saber-AyadEman Abu-Gharbieh
Dec 3, 2020·International Journal of Molecular Sciences·Chary Lopez-PedreraCarlos Pérez-Sánchez
Jan 23, 2021·Journal of Medicinal Chemistry·Zhouling XieChenzhong Liao
Mar 7, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Nicola BorboneGiorgia Oliviero
May 5, 2021·Southern Medical Journal·Tracey D DabalChristopher D Jackson
Sep 21, 2021·Expert Review of Anti-infective Therapy·Ronal Yosua LimenTimotius Ivan Hariyanto
Jun 16, 2021·Current Drug Research Reviews·Ekhlass UddinMd Kudrat-E-Zahan
Nov 28, 2020·Current Drug Targets·Nikita KhannaSandip V Pawar

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.